AI Article Synopsis
- Pulmonary arterial hypertension (PAH) is a serious and rare condition where blood vessels in the lungs malfunction, leading to increased pressure, heart issues, and potentially early death.
- There are three main types of medications for PAH: prostacyclin analogs, endothelin receptor antagonists (ERAs), and phosphodiesterase type 5 inhibitors that boost nitric oxide levels.
- Recent clinical trials are exploring new oral therapies and improved formulations, aiming to review current treatments and highlight recent advancements in these drug classes.
Article Abstract
Pulmonary arterial hypertension (PAH) is a rare, progressively worsening disease characterized by dysfunction among endothelial and smooth muscle cells within the pulmonary vasculature with a resultant increase in pulmonary vascular resistance, right ventricular maladaptation and failure, and ultimately early death. The three major therapeutic classes of medications available to treat PAH act as either prostacyclin analogs or endothelin receptor antagonists (ERAs) or by increasing local nitric oxide (NO) levels by means of phosphodiesterase type 5 inhibitors. Several recent trials have investigated the use of oral prostanoid therapy, next-generation ERAs, and soluble guanylate cyclase stimulators (to increase NO levels) as well as novel formulations of pre-existing therapies. The goal of this manuscript is to briefly review established therapies and then discuss recent developments and practical considerations in each of the major drug classes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11906-014-0496-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!